Obesity, Visceral Clinical Trial
Official title:
Anthropometric And Body Composition Measurements Related To Osteoporosis In Geriatric Population
The patients who consulted to the geriatric outpatient clinic between 2018 and 2019 were
included in the study. The inclusion criterions were being at or over the age of 65 and
diagnosed with osteoporosis according to WHO criteria. Exclusion criteria include vertebral
fracture due to known accidental traumas, history of drug therapy in the past year
(biphosphonate, estrogen replacement therapy, glucocorticoids ), history of co-morbidities as
malignancy, radiotherapy or chemotherapy, renal failure, hyperthyroidism, primer
hyperparathyroidism, rheumatic disease or adrenal diseases.
Initially, a demographic form including age, sex, comorbidities, weight, height was filled by
the participants. Body mass index (BMI, ratio of height and weight, expressed as kg/m2)
calculated. Patients waist and hip circumference was measured (cm).
Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis
(BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan). Skeletal muscle index (SMI) was
calculated from BIA-based skeletal muscle mass with a formula as SMM/height [m2] [8]. ABSI is
measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6) [4].
Osteoporosis was evaluated by using dual energy x-ray absorptiometry (DXA). According to the
T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3
groups as following: a) normal: T-score is greater than -1 SD, b) osteopenia: T-score is
between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
Physical activity levels of patients were evaluated with The Rapid Assessment of Physical
Activity (RAPA) aerobic assessment [9]. Patients divided into 5 groups as following: 1 =
sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular
underactive, and 5 = regular active).
The study protocol was approved by the ethics committee (2018/0478) and all participants gave
written informed consent.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04807959 -
Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program
|
||
| Completed |
NCT06377358 -
Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
|
N/A | |
| Completed |
NCT04754464 -
Clinical Study on the Effect of a Synbiotic on Body Fat Mass
|
N/A | |
| Not yet recruiting |
NCT04942093 -
NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery
|
N/A | |
| Completed |
NCT03239782 -
The "Metabolically-obese Normal-weight" Phenotype and Its Reversal by Calorie Restriction
|
N/A | |
| Completed |
NCT06158191 -
Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study)
|
N/A | |
| Completed |
NCT02833415 -
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
|
Phase 4 | |
| Recruiting |
NCT04100616 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity
|
||
| Completed |
NCT04780828 -
Investigation of the Effects of Different Levels of Obesity on the Respiratory System
|
||
| Completed |
NCT05895916 -
Extreme Exercise and Energy Expenditure (4E) Study
|
N/A | |
| Completed |
NCT04436419 -
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study
|
N/A | |
| Completed |
NCT03038620 -
Impact of Liraglutide 3.0 on Body Fat Distribution
|
Phase 4 | |
| Completed |
NCT04592107 -
The Association of Visceral Adiposity Index With Progression of Chronic Kidney Disease
|
||
| Completed |
NCT03542864 -
Medical Supervised Duodenal-Enteral Feeding Treatment
|
N/A | |
| Completed |
NCT05789888 -
Genes Variability in Obesity and Normal Body Weight Patients.
|